{"id":3830,"date":"2023-12-05T08:30:22","date_gmt":"2023-12-04T21:30:22","guid":{"rendered":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/cbd-not-recommended-for-pain-again-the-placebo-works\/"},"modified":"2025-11-12T21:00:27","modified_gmt":"2025-11-12T10:00:27","slug":"cbd-not-recommended-for-pain-again-the-placebo-works","status":"publish","type":"post","link":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/cbd-not-recommended-for-pain-again-the-placebo-works\/","title":{"rendered":"CBD Not Recommended for Pain \u2013 Again (The placebo works)"},"content":{"rendered":"

Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial.<\/em><\/strong><\/p>\n

View PDF<\/a><\/p>\n

Background: <\/strong>Painful knee osteoarthritis<\/a> (KOA) is common, pharmacological treatment<\/a>, however, is often hampered by limited tolerability. Cannabidiol<\/a>, which preclinically showed anti-inflammatory, analgesic activity<\/a>, could supplement established analgesics<\/a>, but robust clinical trials<\/a> are lacking. The aim of our study was to investigate the effects of oral high-dose CBD administered over 8 weeks on pain, function and patient global assessment as an add-on to continued paracetamol<\/a> in chronic symptomatic KOA.<\/p>\n

Methods: <\/strong>Prospective, randomized, placebo-controlled, double-blind, parallel-group study. Single center, Outpatient Clinic, Department of Special Anaesthesia and Pain Therapy at Medical University of Vienna, Austria. Eligibility criteria included: age: 18\u201398 years; painful KOA; score \u22655 on the pain subscale of the Western Ontario and McMasters Universities Osteoarthritis<\/a> (WOMAC) Index; KOA confirmed by imaging. Participants were on continued dosage of paracetamol 3 g\/d and randomly assigned by web-based software 1:1 to oral cannabidiol 600 mg\/d (n = 43) or placebo (n = 43). Study period: 8 weeks. Primary outcome: Change in WOMAC<\/a> pain subscale scores (0 = no pain, 10 = worst possible pain) from baseline to week 8 of treatment. Trial Registration: ClinicalTrials.gov<\/a> Identifier: NCT04607603<\/a>. Trial is completed.<\/p>\n

Interpretation: <\/strong>In KOA patients, oral high-dose add-on cannabidiol had no additional analgesic effect compared to adding placebo to continued paracetamol. Our results do not support the use of cannabidiol as an analgesic supplement in KOA<\/p>\n

(Source: <\/a>https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666776223001965<\/a><\/strong> )<\/strong><\/p>\n

Also see <\/strong><\/p>\n